Selective endothelial overexpression of arginase ii induces endothelial dysfunction and hypertension and enhances atherosclerosis in mice

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Vaisman, Boris L ^a   Andrews, Karen L ^b   Khong, Sacha M L ^b   Wood, Katherine C ^a   Moore, Xiao L ^b   Fu, Yi ^b   Kepka Lenhart, Diane M ^c   Morris, Sidney M ^c   Remaley, Alan T ^a   Chin Dusting, Jaye P F ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; APOLIPOPROTEIN E; ARGINASE; ARGINASE II; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; C57BL 6 MOUSE; CONTROLLED STUDY; CROSS BREEDING; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME ACTIVITY; FEMALE; GENE CONTROL; GENE OVEREXPRESSION; HUMAN ARGINASE II GENE; HYPERTENSION; KNOCKOUT MOUSE; LIVER; MOUSE; MYOGRAPHY; NONHUMAN; PERITONEUM MACROPHAGE; PROMOTER REGION; SMALL VESSEL MYOGRAPHY; TISSUE LEVEL; TISSUE SPECIFICITY; TRANSGENE; TRANSGENIC MOUSE;

ANIMALS; ARGINASE; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOTTING, WESTERN; ENDOTHELIUM, VASCULAR; HYPERTENSION; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

MUS; MUS MUSCULUS;

EID: 84864050457     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039487     Document Type: Article

References (48)

1. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, et al. (2005) Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 294: 81-90.
2. Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, et al. (2004) Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. Faseb J 18: 1746-1748.
3. Hein TW, Zhang C, Wang W, Chang CI, Thengchaisri N, et al. (2003) Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. Faseb J 17: 2328-2330.
4. Thuraisingham RC, Yaqoob MM, (2003) Oxidative consumption of nitric oxide: a potential mediator of uremic vascular disease. Kidney Int.
5. Johnson FK, Johnson RA, Peyton KJ, Durante W, (2005) Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol.
6. Berkowitz DE, White R, Li D, Minhas KM, Cernetich A, et al. (2003) Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108: 2000-2006.
7. Kim SW, Jeong SJ, Munarriz R, Kim NN, Goldstein I, et al. (2003) Role of the nitric oxide-cyclic GMP pathway in regulation of vaginal blood flow. Int J Impot Res 15: 355-361.
8. Kim NN, Cox JD, Baggio RF, Emig FA, Mistry SK, et al. (2001) Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum. Biochemistry 40: 2678-2688.
9. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, et al. (2008) Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 102: 95-102.
10. Ming XF, Barandier C, Viswambharan H, Kwak BR, Mach F, et al. (2004) Thrombin Stimulates Human Endothelial Arginase Enzymatic Activity via RhoA/ROCK Pathway. Implications for Atherosclerotic Endothelial Dysfunction. Circulation.
11. Ryoo S, Gupta G, Benjo A, Lim HK, Camara A, et al. (2008) Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 102: 923-932.
12. Ryoo S, Lemmon CA, Soucy KG, Gupta G, White AR, et al. (2006) Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res 99: 951-960.
13. Erdely A, Kepka-Lenhart D, Salmen-Muniz R, Chapman R, Hulderman T, et al. (2010) Arginase activities and global arginine bioavailability in wild-type and ApoE-deficient mice: responses to high fat and high cholesterol diets. PLoS One 5: e15253.
14. Teupser D, Burkhardt R, Wilfert W, Haffner I, Nebendahl K, et al. (2006) Identification of macrophage arginase I as a new candidate gene of atherosclerosis resistance. Arterioscler Thromb Vasc Biol 26: 365-371.
15. Pourcet B, Feig JE, Vengrenyuk Y, Hobbs AJ, Kepka-Lenhart D,et al. LXRalpha regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8. Circ Res 109: 492-501.
16. Carvajal N, Cederbaum SD, (1986) Kinetics of inhibition of rat liver and kidney arginases by proline and branched-chain amino acids. Biochim Biophys Acta 870: 181-184.
17. Morris Jr SM, (2009) Recent advances in arginine metabolism: roles and regulation of the arginases. British Journal of Pharmacology 157: 922-930.
18. Huynh NN, Harris EE, Chin-Dusting JFP, Andrews KL, (2009) The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries. Br J Pharmacol 156: 84-93.
19. Iyer RK, Yoo PK, Kern RM, Rozengurt N, Tsoa R, et al. (2002) Mouse model for human arginase deficiency. Mol Cell Biol 22: 4491-4498.
20. Huynh NN, Andrews KL, Head GA, Khong SML, Mayorov DN, et al. (2009) Arginase II knockout mouse displays a hypertensive phenotype despite a decreased vasoconstrictory profile. Hypertension 54: 294-301.
21. Schlaeger TM, Bartunkova S, Lawitts JA, Teichmann G, Risau W, et al. (1997) Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A 94: 3058-3063.
22. Teng PI, Dichiara MR, Komuves LG, Abe K, Quertermous T, et al. (2002) Inducible and selective transgene expression in murine vascular endothelium. Physiol Genomics 11: 99-107.
23. Tain YL, Freshour G, Dikalova A, Griendling K, Baylis C, (2007) Vitamin E reduces glomerulosclerosis, restores renal neuronal NOS, and suppresses oxidative stress in the 5/6 nephrectomized rat. Am J Physiol Renal Physiol 292: F1404-1410.
24. Khong S, Andrews K, Huynh N, Venardos K, Aprico A, et al. (2012) Arginase II inhibition prevents nitrate tolerance. Br J Pharmacol. Jan 31 doi:10.1111/j.1476-5381.2012.01876.x. [Epub ahead of print].
25. Vaisman BL, Klein HG, Rouis M, Berard AM, Kindt MR, et al. (1995) Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem 270: 12269-12275.
26. Zhang WZ, Kaye DM, (2004) Simultaneous determination of arginine and seven metabolites in plasma by reversed-phase liquid chromatography with a time-controlled ortho-phthaldialdehyde precolumn derivatization. Anal Biochem 326: 87-92.
27. Goldstein JL, Ho YK, Basu SK, Brown MS, (1979) Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 76: 333-337.
28. Kepka-Lenhart D, Ash DE, Morris SM, (2008) Determination of mammalian arginase activity. Methods Enzymol 440: 221-230.
29. Morris SM Jr, Kepka-Lenhart D, Chen LC, (1998) Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol 275: E740-747.
30. Lim YC, Garcia-Cardena G, Allport JR, Zervoglos M, Connolly AJ, et al. (2003) Heterogeneity of endothelial cells from different organ sites in T-cell subset recruitment. Am J Pathol 162: 1591-1601.
31. Chen GF, Suzuki H, (1990) Calcium dependency of the endothelium-dependent hyperpolarization in smooth muscle cells of the rabbit carotid artery. J Physiol 421: 521-534.
32. Tawfik HE, Cena J, Schulz R, Kaufman S, (2008) Role of oxidative stress in multiparity-induced endothelial dysfunction. Am J Physiol Heart Circ Physiol 295: H1736-1742.
33. Judkins CP, Diep H, Broughton BR, Mast AE, Hooker EU,et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am J Physiol Heart Circ Physiol 298: H24-32.
34. Vinh A, Widdop RE, Drummond GR, Gaspari TA, (2008) Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res 77: 178-187.
35. Basso F, Amar MJ, Wagner EM, Vaisman B, Paigen B, et al. (2006) Enhanced ABCG1 expression increases atherosclerosis in LDLr-KO mice on a western diet. Biochem Biophys Res Commun 351: 398-404.
36. Anghelina M, Moldovan L, Moldovan NI, (2005) Preferential activity of Tie2 promoter in arteriolar endothelium. J Cell Mol Med 9: 113-121.
37. El Kasmi KC, Qualls JE, Pesce JT, Smith AM, Thompson RW, et al. (2008) Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol 9: 1399-1406.
38. Matsumoto T, D'Uscio L V, Eguchi D, Akiyama M, Smith LA, et al. (2003) Protective effect of chronic vitamin C treatment on endothelial function of apolipoprotein E-deficient mouse carotid artery. J Pharmacol Exp Ther 306: 103-108.
39. Ming X-F, Barandier C, Viswambharan H, Kwak BR, Mach F, et al. (2004) Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 110: 3708-3714.
40. Kim JH, Bugaj LJ, Oh YJ, Bivalacqua TJ, Ryoo S, et al. (2009) Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol 107: 1249-1257.
41. Lim HK, Lim HK, Ryoo S, Benjo A, Shuleri K, et al. (2007) Mitochondrial arginase II constrains endothelial NOS-3 activity. Am J Physiol Heart Circ Physiol 293: H3317-3324.
42. Topal G, Topal J-LG, Brunet A, Walch L, Boucher J-L, et al. (2006) Mitochondrial arginase II modulates nitric-oxide synthesis through nonfreely exchangeable L-arginine pools in human endothelial cells. J Pharmacol Exp Ther 318: 1368-1374.
43. Zhang DX, Mendoza SA, Bubolz AH, Mizuno A, Ge ZD, et al. (2009) Transient receptor potential vanilloid type 4-deficient mice exhibit impaired endothelium-dependent relaxation induced by acetylcholine in vitro and in vivo. Hypertension 53: 532-538.
44. Takaya T, Hirata K, Yamashita T, Shinohara M, Sasaki N, et al. (2007) A specific role for eNOS-derived reactive oxygen species in atherosclerosis progression. Arterioscler Thromb Vasc Biol 27: 1632-1637.
45. Gkaliagkousi E, Douma S, Zamboulis C, Ferro A, (2009) Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertension. J Hypertens 27: 2310-2320.
46. Camilletti A, Moretti N, Giacchetti G, Faloia E, Martarelli D, et al. (2001) Decreased nitric oxide levels and increased calcium content in platelets of hypertensive patients. Am J Hypertens 14: 382-386.
47. Demougeot C, Prigent-Tessier A, Marie C, Berthelot A, (2005) Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens 23: 971-978.
48. Kawashima S, Yokoyama M, (2004) Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol 24: 998-1005.